NASDAQ:IMDZImmune Design Stock Price, Forecast & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Immune Design Corp Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $5.85 0.00 (0.00 %) (As of 04/2/2019) Add Compare Share Today's Range$5.85Now: $5.85▼$5.8550-Day Range$5.85MA: $5.85▼$5.8552-Week Range$1.10Now: $5.85▼$5.85VolumeN/AAverage Volume374,216 shsMarket Capitalization$282.96 millionP/E RatioN/ADividend YieldN/ABeta3.48 ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Immune Design Corp., a clinical-stage immunotherapy company, engages in the research and development of in vivo treatments for cancer. The company primarily develops oncology product candidates based on its ZVex and GLAAS discovery platforms. Its lead products include CMB305, a cancer vaccine targeting the NY-ESO-1 tumor antigen, which is in Phase 2 trial for the treatment of patients with synovial and MRCL sarcoma as a monotherapy; and G100, an antigen agnostic intratumoral product candidate as a monotherapy and combination therapy for the treatment of patients with follicular non-Hodgkin Lymphoma. The company is also developing CA21, a multi-targeting prime boost for the treatment of multiple solid tumors; and ZVex-IL12 for the treatment of TBD tumors. In addition, its technologies are used in the fields of infectious and allergic diseases. The company has license agreements with California Institute of Technology, University of North Carolina at Chapel Hill, TheraVectys SA, Infectious Disease Research Institute, MedImmune LLC, and Sanofi; and a collaboration agreement with Sanofi Pasteur. Immune Design Corp. was founded in 2008 and is headquartered in Seattle, Washington.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Immune Design. Previous Next 3.1 Community Rank Outperform VotesImmune Design has received 341 “outperform” votes. (Add your “outperform” vote.)Underperform VotesImmune Design has received 215 “underperform” votes. (Add your “underperform” vote.)Community SentimentImmune Design has received 61.33% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Immune Design and other stocks. Vote “Outperform” if you believe IMDZ will outperform the S&P 500 over the long term. Vote “Underperform” if you believe IMDZ will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldImmune Design does not currently pay a dividend.Dividend GrowthImmune Design does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Immune Design insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 18.10% of the stock of Immune Design is held by insiders.Percentage Held by Institutions61.72% of the stock of Immune Design is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Immune Design are expected to decrease in the coming year, from ($1.15) to ($1.16) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immune Design is -3.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immune Design is -3.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmune Design has a P/B Ratio of 3.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.82 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:IMDZ Previous Symbol CUSIPN/A CIK1437786 Webwww.immunedesign.com Phone206-682-0645Debt Debt-to-Equity RatioN/A Current Ratio11.33 Quick Ratio11.32Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$2.20 million Price / Sales128.62 Cash FlowN/A Price / Cash FlowN/A Book Value$1.91 per share Price / Book3.06Profitability EPS (Most Recent Fiscal Year)($1.75) Net Income$-54,760,000.00 Net Margins-2,483.00% Return on Equity-49.56% Return on Assets-46.21%Miscellaneous Employees48 Outstanding Shares48,370,000Market Cap$282.96 million Next Earnings DateN/A OptionableOptionable Receive IMDZ News and Ratings via Email Sign-up to receive the latest news and ratings for IMDZ and its competitors with MarketBeat's FREE daily newsletter. Immune Design (NASDAQ:IMDZ) Frequently Asked Questions How were Immune Design's earnings last quarter? Immune Design Corp (NASDAQ:IMDZ) issued its earnings results on Wednesday, August, 1st. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.01. The biotechnology company earned $0.76 million during the quarter, compared to analysts' expectations of $0.64 million. Immune Design had a negative net margin of 2,483.00% and a negative return on equity of 49.56%. View Immune Design's earnings history. Has Immune Design been receiving favorable news coverage? News coverage about IMDZ stock has been trending positive on Wednesday, InfoTrie reports. The research firm ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Immune Design earned a media sentiment score of 2.2 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news about Immune Design. Who are some of Immune Design's key competitors? Some companies that are related to Immune Design include DiaMedica Therapeutics (DMCAF), Akero Therapeutics (AKRO), BioXcel Therapeutics (BTAI), I-Mab (ARQT), Arcus Biosciences (RCUS), Enanta Pharmaceuticals (ENTA), Phibro Animal Health (PAHC), Aimmune Therapeutics (AIMT), Arcturus Therapeutics (ARCT), Athenex (ATNX), Humanigen (HGEN), Nabriva Therapeutics (NBRV), Amphastar Pharmaceuticals (AMPH), Rhythm Pharmaceuticals (RYTM) and VBI Vaccines (VBIV). View all competitors. What other stocks do shareholders of Immune Design own? Based on aggregate information from My MarketBeat watchlists, some companies that other Immune Design investors own include Omeros (OMER), Progenics Pharmaceuticals (PGNX), Trevena (TRVN), Geron (GERN), Melinta Therapeutics (MLNT), Rigel Pharmaceuticals (RIGL), Selecta Biosciences (SELB), Synergy Pharmaceuticals (SGYP), TG Therapeutics (TGTX) and TherapeuticsMD (TXMD). Who are Immune Design's key executives? Immune Design's management team includes the following people: Dr. Carlos V. Paya, CEO, Pres & Director (Age 60)Mr. Stephen R. Brady, Exec. VP of Strategy & Fin. (Age 49)Dr. Jan Henrik Ter Meulen, Chief Scientific Officer (Age 56)Sylvia Wheeler, Investor Relations OfficerDr. Wayne R. Gombotz, Chief Devel. Officer (Age 60) What is Immune Design's stock symbol? Immune Design trades on the NASDAQ under the ticker symbol "IMDZ." What is Immune Design's stock price today? One share of IMDZ stock can currently be purchased for approximately $5.85. How big of a company is Immune Design? Immune Design has a market capitalization of $282.96 million and generates $2.20 million in revenue each year. The biotechnology company earns $-54,760,000.00 in net income (profit) each year or ($1.75) on an earnings per share basis. Immune Design employs 48 workers across the globe. What is Immune Design's official website? The official website for Immune Design is www.immunedesign.com. How can I contact Immune Design? Immune Design's mailing address is 1616 EASTLAKE AVENUE EAST SUITE 310, SEATTLE WA, 98102. The biotechnology company can be reached via phone at 206-682-0645 or via email at [email protected] This page was last updated on 7/15/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
